NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
Sellas Life Sciences Group
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.